StonvexLoading…
StonvexStonvexStonvexCore line items from ACRS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $7.83M | $18.72M | $31.25M | $29.75M |
Operating Income | $-76.38M | $-141.93M | $-97.36M | $-89.85M |
Net Income | $-64.92M | $-132.06M | $-88.48M | $-86.91M |
EPS (Diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 |
Total Assets | $160.46M | $220.33M | $197.41M | $254.60M |
Total Liabilities | $57.38M | $64.77M | $40.23M | $56.98M |
Cash & Equivalents | $19.96M | $24.57M | $39.88M | $45.28M |
Free Cash Flow OCF − CapEx | $-47.22M | $-20.20M | $-79.63M | $-68.17M |
Shares Outstanding | 120.50M | 107.85M | 70.89M | 66.69M |